Canadian Journal of Gastroenterology and Hepatology最新文献

{"title":"Comparison of Endoscopic Radiofrequency Ablation and Argon Plasma Coagulation in Patients with Gastric Low-Grade Intraepithelial Neoplasia: A Large-Scale Retrospective Study.","authors":"Nanjun Wang,&nbsp;Ningli Chai,&nbsp;Longsong Li,&nbsp;Huikai Li,&nbsp;Yaqi Zhai,&nbsp;Xiuxue Feng,&nbsp;Shengzhen Liu,&nbsp;Wengang Zhang,&nbsp;Enqiang Linghu","doi":"10.1155/2022/2349940","DOIUrl":"https://doi.org/10.1155/2022/2349940","url":null,"abstract":"<p><strong>Background: </strong>Gastric low-grade intraepithelial neoplasia (LGIN) is a precancerous lesion of gastric cancer. Endoscopic therapies represented by radiofrequency ablation (RFA) and argon plasma coagulation (APC) have been applied to treat gastric LGIN in recent years. However, no comparative study examining the effectiveness and safety profiles of RFA and APC has been reported.</p><p><strong>Methods: </strong>A single-center, large-scale, retrospective study, including 73 and 50 patients treated with RFA and APC, respectively, was conducted in the First Medical Center of Chinese PLA General Hospital from October 2015 to October 2020, with a two-year follow-up. Effectiveness, complications, operative factors, and other data were assessed.</p><p><strong>Results: </strong>At 2 years of follow-up, cure, relapse, recurrence, and progression rates were 90.4%, 9.6%, 9.6%, and 2.7% in the RFA group, respectively, versus 90%, 10%, 12%, and 4% in the APC group, respectively, with no statistically significant differences between the two groups (all <i>p</i> > 0.05). However, the mean lesion size was significantly larger in the RFA group (2.6 ± 1.0 cm) than in the APC group (1.5 ± 0.6 cm) (<i>p</i> < 0.001); there was also a significant difference in the composition ratio of large lesions between the two groups (<i>p</i> < 0.001). No serious postoperative complications showed in either group, and the abdominal pain was the most common symptom in the short term after surgery.</p><p><strong>Conclusions: </strong>RFA and APC are both safe and effective destructive therapies for gastric LGIN. RFA is more suitable for flat and large lesions, while APC is more suitable for small lesions, especially those with slight local uplift or depression. An intraoperative submucosal injection is expected to be an effective method for relieving postoperative abdominal pain.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242788/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40476001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors and Timing of Additional Surgery after Noncurative ESD for Early Gastric Cancer.","authors":"Kaipeng Duan,&nbsp;Dongbao Li,&nbsp;Dongtao Shi,&nbsp;Jie Pei,&nbsp;Jiayu Ren,&nbsp;Weikang Li,&nbsp;Anqi Dong,&nbsp;Tao Chen,&nbsp;Jin Zhou","doi":"10.1155/2022/3421078","DOIUrl":"https://doi.org/10.1155/2022/3421078","url":null,"abstract":"<p><strong>Background: </strong>Patients with early gastric cancer undergoing noncurative endoscopic submucosal dissection (ESD) have a risk of tumor recurrence and metastasis, and some patients need additional surgery. The purpose of this study was to explore the risk factors of cancer residue and lymph node (LN) metastasis after noncurative ESD for early gastric cancer and to compare the short outcome of early and delayed additional surgery.</p><p><strong>Methods: </strong>The clinicopathological characteristics of 30 early gastric cancer patients who received noncurative ESD and additional surgery were studied retrospectively. Multivariable regression was utilized to examine the independent risk factors for residual cancer and LN metastasis. Receiver operating characteristic curve was used to analyze the multivariable model's predictive performance. Furthermore, the perioperative safety and radical tumor performance of early surgery (≤30 days, <i>n</i> = 11), delayed surgery (>30 days, <i>n</i> = 11) after ESD, and upfront surgery (<i>n</i> = 59) were compared.</p><p><strong>Results: </strong>Multivariable regression showed that diffuse type of Lauren classification, submucosal invasion, and positive human epidermal growth factor receptor-2 (HER-2) were risk factors for residual cancer. Undifferentiated carcinoma, vascular invasion, and positive vertical margin were risk factors for LN metastasis. The area under the curve (AUC) of the multifactor model predicting cancer residue and LN metastasis was 0.761 and 0.792, respectively. The early surgery group experienced higher intraoperative blood loss and a longer operation time than the delayed surgery and upfront surgery groups. There was no significant difference in the number of LN dissections, LN metastasis rate, and postoperative complications among the three groups.</p><p><strong>Conclusion: </strong>Diffuse type of Lauren classification, submucosal invasion, and positive HER-2 are risk factors for residual cancer, while undifferentiated carcinoma, vascular invasion, and positive vertical margin are risk factors for LN metastasis. Delayed additional surgery after ESD (>30 days) has higher intraoperative safety, without affecting the radical resection in early gastric cancer patients.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40551750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usefulness of Noncontrast MRI-Based Radiomics Combined Clinic Biomarkers in Stratification of Liver Fibrosis.","authors":"Ru Zhao,&nbsp;Hong Zhao,&nbsp;Ya-Qiong Ge,&nbsp;Fang-Fang Zhou,&nbsp;Long-Sheng Wang,&nbsp;Hong-Zhen Yu,&nbsp;Xi-Jun Gong","doi":"10.1155/2022/2249447","DOIUrl":"https://doi.org/10.1155/2022/2249447","url":null,"abstract":"<p><strong>Purpose: </strong>To develop and validate a radiomic nomogram based on texture features from out-of-phase T1W images and clinical biomarkers in prediction of liver fibrosis.</p><p><strong>Materials and methods: </strong>Patients clinically diagnosed with chronic liver fibrosis who underwent liver biopsy and noncontrast MRI were enrolled. All patients were assigned to the nonsignificant fibrosis group with fibrosis stage <2 and the significant fibrosis group with stage ≥2. Texture parameters were extracted from out-of-phase T1-weighted (T1W) images and calculated using the Artificial Intelligent Kit (AK). Boruta and LASSO regressions were used for feature selection and a multivariable logistic regression was used for construction of a combinational model integrating radiomics and clinical biomarkers. The performance of the models was assessed by using the receiver operator curve (ROC) and decision curve.</p><p><strong>Results: </strong>ROC analysis of the radiomics model that included the most discriminative features showed AUCs of the training and test groups were 0.80 and 0.78. A combinational model integrating RADscore and fibrosis 4 index was established. ROC analysis of the training and test groups showed good to excellent performance with AUC of 0.93 and 0.86. Decision curves showed the combinational model added more net benefit than radiomic and clinical models alone.</p><p><strong>Conclusions: </strong>The study presents a combinational model that incorporates RADscore and clinical biomarkers, which is promising in classification of liver fibrosis.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40551749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antiviral Therapy for a Postpartum Flare in Women with Chronic HBV Infection Shortens the ALT Recovery Time and Reduces Hepatitis Re-Flare Rates within 4 years.","authors":"Min Quan, Cong Liu, Wei Li, Hui-Chun Xing","doi":"10.1155/2022/4753267","DOIUrl":"10.1155/2022/4753267","url":null,"abstract":"<p><strong>Background: </strong>Few studies explored whether anti-hepatitis B virus (HBV) therapy should be initiated during postpartum hepatitis flare.</p><p><strong>Aim: </strong>This study aimed to analyze the effect of anti-HBV therapy on postpartum hepatitis flare and evaluate the prognosis within 4 years postpartum.</p><p><strong>Methods: </strong>This retrospective study enrolled hepatitis B surface antigen (HBsAg)-positive and hepatitis B e antigen (HBeAg)-positive pregnant women with HBV DNA ≥ 10⁶ IU/mL. A total of 152 pregnant women were included: 103 in the prophylactic anti-HBV therapy group (PT-G) and 49 in the non-prophylactic anti-HBV therapy group (NPT-G). The women with a postpartum flare were assigned to the anti-HBV therapy group (AT-G) and non-anti-HBV therapy group (NAT-G) to analyze the effect of postpartum anti-HBV therapy on hepatitis flare. Virological and biochemical parameters were assessed.</p><p><strong>Results: </strong>Taking postpartum 12 weeks as the cutoff point, the ALT recovered time for postpartum flare women is shorter in AT-G (<i>n</i> = 16, 42.1%) or PT-G (<i>n</i> = 23, 34.8%) than in NAT-G (<i>n</i> = 14, 23.0%; <i>x</i> ² = 4.067, <i>P</i>=0.044) or NPT-G (<i>n</i> = 4, 11.1%; <i>x</i> ² = 5.579, <i>P</i>=0.018). Taking postpartum 26 weeks as the cutoff point, the ALT recovered time is shorter in AT-G (<i>n</i> = 35, 57.3%) or PT-G (<i>n</i> = 44, 66.7%) than in NAT-G (<i>n</i> = 32, 84.2%; <i>x</i> ² = 7.707, <i>P</i>=0.006) or NPT-G (<i>n</i> = 16, 44.4%; <i>x</i> ² = 4.749, <i>P</i>=0.029). Postpartum flare recovery time was positively correlated with HBV DNA level at delivery [<i>r</i> = 0.223, <i>P</i>=0.025, 95%CI (0.022～0.41)]. The hepatitis re-flare rates within postpartum 4 years in AT-G (<i>n</i> = 3, 9.68%) is lower than that in NAT-G (<i>n</i> = 24, 45.4%; <i>x</i> ² = 14.003, <i>P</i> ≤ 0.001). The HBeAg, HBsAg, HBV DNA, and ALT level at postpartum 4 years in AT-G were lower than that in NAT-G (<i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>Anti-HBV therapy for postpartum hepatitis flare of women with chronic HBV could shorten the ALT recovery time and reduce hepatitis re-flare rates within 4 years of postpartum.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40406416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Modified Glasgow Prognostic Score Predicts Survival in Gastric Cancer Patients with Normal CEA and CA19-9.","authors":"Shun Zhang,&nbsp;Jing-Ze Li,&nbsp;Tao Du,&nbsp;Hai-Qiang Li,&nbsp;Ren-Hao Hu,&nbsp;Chi-Ye Ma,&nbsp;Xi-Mao Cui,&nbsp;Chun Song,&nbsp;Xiao-Hua Jiang","doi":"10.1155/2022/3953004","DOIUrl":"https://doi.org/10.1155/2022/3953004","url":null,"abstract":"<p><strong>Background: </strong>Traditionally, serum CEA and CA19-9 levels are good prognostic factors for gastric cancer. Many gastric cancer patients do not have elevated CEA or CA19-9 levels even at a very advanced stage. This study investigates the significance of the modified Glasgow prognostic score (mGPS) for the survival of gastric cancer patients with normal CEA and CA19-9.</p><p><strong>Methods: </strong>We retrospectively examined 488 curatively resected gastric cancer patients with normal preoperative serum levels of CEA and CA19-9 to evaluate the prognostic ability of mGPS for overall survival. The prognostic significance was analyzed by univariate and multivariate analyses.</p><p><strong>Results: </strong>Age, hemoglobin, white cell count, and neutrophils were each significantly correlated with the mGPS. Multivariate analyses showed that tumor location (HR, 0.803; 95% CI, 0.667-0.966; <i>P</i>=0.020), TNM stage (HR, 2.714; 95% CI, 2.250-3.275; <i>P</i> < 0.001), and mGPS (HR, 1.042; 95% CI, 1.105-1.772; <i>P</i>=0.023) were significantly associated with overall survival. Significant correlations were found between overall survival and mGPS. The Kaplan-Meier analysis demonstrated significant differences among patients with mGPS of 0, 1, and 2 (<i>P</i> < 0.001), with the mortality rate being higher for patients with a higher mGPS.</p><p><strong>Conclusion: </strong>The mGPS can predict survival in gastric cancer patients with normal CEA and CA19-9.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40225037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of Half-Transected and Self-Pulling Esophagojejunostomy in Total Laparoscopic Gastrectomy for Gastric Cancer: A Safe and Feasible Technique.","authors":"Hongtao Wan,&nbsp;Jianyong Xiong,&nbsp;Yanglin Chen,&nbsp;Haiyun Wei,&nbsp;Ren Tang,&nbsp;Chao Chen,&nbsp;Qing Sun,&nbsp;Jing Xu,&nbsp;Bo Yi","doi":"10.1155/2022/2422274","DOIUrl":"https://doi.org/10.1155/2022/2422274","url":null,"abstract":"<p><strong>Objective: </strong>This study introduces a technique for esophagojejunostomy with half transected and self-pulling (HTSP) and evaluates the safety, feasibility, and clinical results of this technique in totally laparoscopic total gastrectomy (TLTG).</p><p><strong>Materials and methods: </strong>From May 2019 to March 2021, 42 patients (HTSP group) who underwent HTSP-TLTG surgery in the Department of Abdominal Tumor Surgery of Jiangxi Cancer Hospital were included in this study. The control group consisted of 50 patients undergoing conventional TLTG surgery (conventional anastomosis group) performed by the same surgical team from March 2018 to March 2020. The clinical data of the two groups were retrospectively analyzed and compared.</p><p><strong>Results: </strong>The mean operation time of the HTSP-TLTG surgery was 166.7 ± 13.1 minutes and the anastomosis time was 20.8 ± 2.0 minutes, which were significantly shorter than those of traditional TLTG (<i>P</i> < 0.05). There were no significant differences between the two groups in blood loss, time to first exhaust, postoperative hospital stay, and incidence of surgery-related complications.</p><p><strong>Conclusion: </strong>HTSP is a safe and feasible way of endoscopic esophagojejunal anastomosis, which requires a relatively low suture technique under endoscopy, and is suitable for promotion.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40225038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Albumin Paclitaxel Compared with 5-Penfluorouracil, Lobaplatin, and Albumin Paclitaxel Combined with 5-Penfluorouracil in the Treatment of Human Gastric Cancer Cell AGS Line Autophagy and Apoptosis.","authors":"Xingzhen Cheng,&nbsp;Fang Yang,&nbsp;Yang Wang,&nbsp;Wei Nie,&nbsp;Adarsha Mahendra Upadhyay,&nbsp;Maolin Zhang,&nbsp;Qian Wang,&nbsp;Zhiqiang Yan","doi":"10.1155/2022/6015877","DOIUrl":"https://doi.org/10.1155/2022/6015877","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer is one of the most common malignant tumors in the world. Albumin paclitaxel (Nab-PTX) is a novel microtubule inhibitor with albumin as the carrier. Several clinical trials are underway in gastric cancer, but the autophagy mechanism of Nab-PTX on gastric cancer is still unclear. The autophagy and apoptosis effects of Nab-PTX compared with 5-pentafluorouracil (5-Fu) and lobaplatin (LBP) in gastric cancer are also unclear.</p><p><strong>Objective: </strong>This article will compare the effects of Nab-PTX, 5-Fu, LBP, and albumin paclitaxel + 5-pentafluorouracil (Nab-PTX + 5-Fu) on AGS cells from the perspective of autophagy and apoptosis, which is to provide new ideas and experimental evidence for gastric cancer.</p><p><strong>Method: </strong>(1) Experimental groups were control (Ctrl), Nab-PTX, 5-Fu, LBP, and Nab-PTX + 5-Fu. (2) CCK-8 assay was used to reflect cell viability and proliferation. (3) The flow cytometry was used to perform the 24-hour apoptosis and cell cycle of each group. (4) Western blot assay was used to investigate autophagy signal proteins LC3I/LC3II, LC3II/LC3I, SQSTM1/p62, Beclin-1, Atg12, Atg5, p-mULK1, p-AMPK, p-mTOR, and apoptosis signal proteins Bax and Bcl-2.</p><p><strong>Results: </strong>Nab-PTX, 5-Fu, LBP, and Nab-PTX + 5-Fu inhibited AGS cells' proliferation and arrested the cell cycle. At the same time, each group increased the apoptosis of AGS cells to various degrees (Nab-PTX + 5-Fu > Nab-PTX > 5-Fu > LBP, respectively). The experimental results showed that Nab-PTX and Nab-PTX + 5-Fu promoted autophagy and apoptosis of AGS cells. The comparison of Nab-PTX, 5-Fu, and LBP between groups revealed that 5-Fu inhibited autophagy and the expression of apoptosis protein Bax. In LBP, abnormal activation of autophagy downstream, blocking of autophagy flow, abnormal increase of ATG12, and increased expression of apoptosis protein Bax occurred. Further study found that the autophagy upstream mechanism is different.</p><p><strong>Conclusion: </strong>Nab-PTX, 5-Fu, LBP, and Nab-PTX + 5-Fu can inhibit cell proliferation, promote cell apoptosis, and induce the difference in autophagy expression. The autophagy difference of this antitumor drug may be related to its inducing apoptosis. Meanwhile, Nab-PTX has a better antitumor effect than 5-Fu and LBP in gastric cancer, and the combination of Nab-PTX + 5-Fu has more antitumor advantages.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40012227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Computed Tomography Images of Spontaneous Portosystemic Shunt in Liver Cirrhosis.","authors":"Fangfang Yi, Xiaozhong Guo, Qing-Lei Zeng, Benqiang Yang, Yanglan He, Shanshan Yuan, Ankur Arora, Xingshun Qi","doi":"10.1155/2022/3231144","DOIUrl":"10.1155/2022/3231144","url":null,"abstract":"<p><p>Spontaneous portosystemic shunt (SPSS) refers to collateral vessels that communicate between the portal vein system and systemic circulation. SPSS mainly includes esophageal varices, gastric varices, left gastric vein, recanalized paraumbilical vein, abdominal wall varices, and spontaneous splenorenal shunt. SPSS contributes to the development of hepatic encephalopathy caused by portal vein inflow bypassing and carries a higher risk of death in liver cirrhosis. Abdominal contrast-enhanced computed tomography is a major imaging approach to establish a diagnosis of SPSS and evaluate its location and feature. This review primarily describes the main contrast-enhanced CT features of SPSS in liver cirrhosis.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200601/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40012326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clostridioides difficile Infection in Liver Cirrhosis: A Concise Review","authors":"Yuanbin Liu, Mingkai Chen","doi":"10.1155/2022/4209442","DOIUrl":"https://doi.org/10.1155/2022/4209442","url":null,"abstract":"Clostridium difficile is a Gram-positive bacillus with fecal-oral transmission and is currently one of the most common nosocomial infections worldwide, which was renamed Clostridioides difficile in 2016. Clostridioides difficile infection (CDI) is a prevalent infection in cirrhosis and negatively affects prognosis. This study aimed to provide a concise review with clinical practice implications. The prevalence of CDI in cirrhotic patients increases, while the associated mortality decreases. Multiple groups of risk factors increase the likelihood of CDI in patients with cirrhosis, such as antibiotic use, the severity of cirrhosis, some comorbidities, and demographic aspects. Treatment in the general population is currently described in the latest guidelines. In patients with cirrhosis, rifaximin and lactulose have been shown to reduce CDI risk due to their modulatory effects on the intestinal flora, although conflicting results exist. Fecal microbiota transplantation (FMT) as a treatment for the second or subsequent CDI recurrences has demonstrated a good safety and efficacy in cirrhosis and CDI. Future validation in more prospective studies is needed. Screening of asymptomatic patients appears to be discouraged for the prevention currently, with strict hand hygiene and cleaning of the ward and medical equipment surfaces being the cornerstone of minimizing transmission.","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90712194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Challenges of <i>Helicobacter pylori</i> Infection in Ethiopia: A Community-Based Cross-Sectional Study.","authors":"Esayas Kebede Gudina,&nbsp;Hiwot Amare,&nbsp;Solomon Ali,&nbsp;Melkamu Berhane Arefayine,&nbsp;Dagmawi Tewolde,&nbsp;Million Tesfaye Eshete,&nbsp;Mulusew Gerbaba Jebena,&nbsp;Andreas Wieser,&nbsp;Guenter Froeschl,&nbsp;Markos Tesfaye,&nbsp;Hailemichael Desalegn,&nbsp;Mulatu Gashaw","doi":"10.1155/2022/4013020","DOIUrl":"https://doi.org/10.1155/2022/4013020","url":null,"abstract":"<p><strong>Background: </strong>In resource-constrained countries, accurate diagnosis of <i>Helicobacter pylori</i> infection remains a challenge. This study aimed to assess the clinical utility of locally available serological and stool antigen test kits in the management of people with suspected <i>H. pylori</i> infection in Ethiopia.</p><p><strong>Methods: </strong>A community-based cross-sectional study was conducted with apparently healthy adults and children living in southwest Ethiopia. Participants were interviewed for dyspepsia symptoms and related clinical conditions. <i>H. pylori</i> infection was examined using commercially available serological and stool antigen tests. The association between <i>H. pylori</i> tests and dyspepsia symptoms was analyzed using logistic regression models.</p><p><strong>Results: </strong>Out of 1392 participants included in the final analysis, 49.1% and 6.5% tested positive for <i>H. pylori</i> infection with serology and stool antigen test kits, respectively. Participants reporting epigastric symptoms in the past three months (AOR = 1.93, 95% CI = 1.28-2.91) and those with recent dyspepsia treatment (AOR = 1.51, 95% CI = 1.05-2.18) were likely to have positive serology test. However, no association between dyspepsia symptoms and <i>H. pylori</i> stool antigen positivity was observed in our study.</p><p><strong>Conclusion: </strong>ccurate detection of <i>H. pylori</i> infections using commercially accessible diagnostics remains difficult in Ethiopia. With these methods, it will be hard to ensure adequate diagnosis and early treatment of <i>H. pylori</i> infection, as well as rational antibiotic use.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553705/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33515097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}